

Date: January 3, 2002

Page 1 of 1

Form PTO-1449 (REV. 07/01)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. HSS-022XX	APPLICATION NO. 09/937,191
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT: Walter Schubert	
		FILING DATE: September 21, 2001	GROUP:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	WO 98/44923* ✓	10/15/1998	WIPO			X
	EP 0 167 936 A2*	01/15/1986	EPO			X
my	GB 1 540 019** ✓	02/07/1979	Great Britain			X

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

my	Effect of ubenimex on the immune system of patients with hematological malignancies. T. Yamazaki et al., <i>Biomed & Pharmacoth.</i> , (1991), 45, 105-112.*
	Potent Homophthalimide-Type Inhibitors of B16F10 L5 Mouse Melanoma Cell Invasion. H. Kagechika et al., <i>Biol. Pharm. Bull.</i> , (1999), 22(9), 1010-1012.*
	Inhibition of Alanyl Aminopeptidase Induces MAP-Kinase p42 ERK2 in the Human T Cell Line KARPAS-299. U. Lendeckel et al., <i>Biochemical and Biophysical Research Communications</i> , (1998), 252(1), 5-9.*
	Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin). J. Yoneda et al., <i>Clinical & Experimental Metastasis</i> , (1992), 10(1), 49-59.**
	Aminopeptidase Inhibitor Ubenimex (Bestatin) Inhibits the Growth of Human Choriocarcinoma in Nude Mice through its Direct Cytostatic Activity. K. Ino et al., <i>Anticancer Research</i> , (1995), 15, 2081-2087.** ✓
	Antitumor Activity of Actinonin <i>in Vitro</i> and <i>in Vivo</i> . Y. Xu et al., <i>Clinical Cancer Research</i> , (Jan. 1998), 4, 171-176.**
✓	Inhibition of Tumor Cell Invasion and Matrix Degradation by Aminopeptidase Inhibitors. H. Fujii et al., <i>Biol. Pharm. Bull.</i> , (1996), 19(1), 6-10.
EXAMINER	misook y
	DATE CONSIDERED 10-16-04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.